Stanislav Gobec

TL;DR: This review deals with the cytoplasmic steps of peptidoglycan biosynthesis and the chemical and enzymatic synthesis of the nucleotide precursor substrates that are not commercially available and the search for specific inhibitors that could act as antibacterial compounds.

TL;DR: The crystal structure of human BChE in complex with compound (+)-1 was solved, revealing the binding mode and providing clues for potential optimization and suggesting that compound 1 represents a promising candidate for hit-to-lead follow-up in the drug-discovery process against Alzheimer's disease.

TL;DR: Compound 3 crosses the blood-brain barrier, and it improves memory, cognitive functions, and learning abilities of mice in a scopolamine model of dementia, and is thus a promising advanced lead compound for the development of drugs for alleviating symptoms of cholinergic hypofunction in patients with advanced Alzheimer's disease.

TL;DR: This study provides an advanced lead compound for developing drugs for alleviating symptoms caused by cholinergic hypofunction in advanced AD and moderately crosses the blood-brain barrier and improves memory, cognitive functions and learning abilities of mice in a model of the cholinerential deficit that characterizes AD.

TL;DR: In this paper, a review summarizes recent developments in cathepsin B inhibition, including the use of X-ray crystal structures of C-PETs with protein inhibitors, and the design and synthesis of many new small-molecular-weight compounds as inhibitors of C -PETs.